TXN and neoplasm: The thioredoxin system has emerged as an important target in cancer chemotherapy, because both Trx1 and TrxR1 have been shown to be overexpressed in a variety of human cancer types and associated with increased tumor growth, drug resistance and poor patient prognosis [19, 23, 42, 43].